Fundz

Real-time funding, M&A, exec moves & hiring — the signals that move deals

More real-time opportunities that match your ICP — every funding, M&A, and exec move the moment it breaks, with the verified contacts to reach out first.

The funding market, moving in real timeBook a DemoStart with Pro — $79/mo
Loading live signals…

Funding, M&A, exec moves & hiring — every signal Fundz sees, the moment it happens. See who’s in your market, who to reach, and why now.

Back to SEC Filings
Executive ChangeItem 5.02 · 8-KLOW RiskPositive

MYRIAD GENETICS, INC.

Filed: Jun 4, 2026CIK: 0000899923
View on SEC.gov

AI Executive Summary

AI-powered analysis of 8-K filing content

Myriad Genetics stockholders approved an amendment to the 2012 Employee Stock Purchase Plan on June 4, 2026, authorizing an additional 4,000,000 shares for issuance. This action reflects the company's commitment to employee retention and engagement through enhanced equity compensation.

Key Takeaways

4,000,000 additional shares authorized under the 2012 Employee Stock Purchase Plan

Amendment approved at the 2026 Annual Meeting of Stockholders on June 4, 2026

2 more takeaways

Filing Overview

Form Type8-K
Filing DateJun 4, 2026
Item5.02
CategoryExecutive Change
CIK0000899923
Accession #mygn-20260604
Risk LevelLOW
SentimentPositive
Signalinformational
Topics
stock offering

What This Means

A senior executive (CEO, CFO, etc.) has joined, departed, or changed roles. Leadership changes can significantly impact strategy.
View Full Filing on SEC.govBrowse More Filings